Pacific Edge Ltd. is a pharmaceutical company in New Zealand with a high risk ESG score of 31.1. They specialize in developing and selling diagnostic tools for early cancer detection. The company operates in two main segments: Commercial, focusing on sales and marketing worldwide, and Research, dedicated to creating new cancer diagnostic products. Their flagship product, Cxbladder, is available in the United States, New Zealand, and other international markets.